Business
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions, today announced that its wholly-owned subsidiary, Aeterna Zentaris GmbH, has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited (“Wuzhou”) for the commercialization of Macrilen® (macimorelin) in Hong Kong
About this update from Cosciens Biopharma Inc.
[{"type":"image","alt":"COSCIENS Biopharma Inc.","displaySize":"","headline":null,"caption":"COSCIENS Biopharma Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/c1c23173d064dcced5831bb963ac66d2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ysOkqPWcXyAzP0v2M3xkkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c1c23173d064dcced5831bb963ac66d2","width":300,"height":115}},"lazy":false},{"type":"text","content":"TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions, today announced that its wholly-owned subsidiary, Aeterna Zentaris GmbH, has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited (“Wuzhou”) for the commercialization of Macrilen® (macimorelin) in Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan.","length":575,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Wuzhou will be responsible for the registration, importation, and commercialization of Macrilen® (macimorelin), the Company’s oral diagnostic test for Adult Growth Hormone Deficiency (“AGHD”), within the designated territories. This partnership leverages the "Hong Kong and Macao Medicine and Equipment Connect" policy, allowing for expedited market access in the Guangdong-Hong Kong-Macao Greater Bay Area. The agreement is for an initial ten-year term and includes a commitment by Wuzhou for a minimum initial order of approximately €800,000.","length":588,"tagName":"p"},{"type":"text","content":"COSCIENS Management Commentary","length":30,"tagName":"p"},{"type":"text","content":"Dr. Matthias Gerlach, Senior Vice-President and Managing Director of Aeterna Zentaris GmbH commented: “We are very pleased to partner with Wuzhou, with their proven track record in the Greater China region and Southeast Asia, deep regulatory expertise and strong commercial presence in the Greater Bay Area and Singapore specifically. This agreement represents a key step in our strategy to unlock the global potential of Macrilen® and to build sustainable, long -term rev...